Determinants of low health-related quality of life in patients with myelodysplastic syndromes : EUMDS Registry study
© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved..
Patients with myelodysplastic syndromes (MDS) frequently experience a significant symptom burden, which reduces health-related quality of life (HRQoL). We aimed to identify determinants of low HRQoL in patients recently diagnosed with MDS, for guiding early intervention strategies. We evaluated longitudinal data in 2205 patients with MDS during their first year after diagnosis. Median values of EQ-5D 3-level (EQ-5D-3L) index (0.78) and visual analog scale (VAS) score (0.70) were used as thresholds for low HRQoL. In addition, the 5 dimensions of EQ-5D-3L were analyzed for impairments (any level vs "no problem" category). After multiple imputation of missing values, we used generalized estimating equations (GEE) to estimate odds ratios (OR) for univariable determinant screening (P < .15), and to subsequently derive multivariable models for low HRQoL with 95% confidence intervals (CI). Multivariable GEE analysis showed the following independent determinants (OR, 95% CI) for low EQ-5D index: increased age (60-75 years: 1.33, 1.01-1.75; >75: 1.84, 1.39-2.45), female sex (1.70, 1.43-2.03), high serum ferritin level (≥1000 vs ≤300 μg/L: 1.41, 1.06-1.87), comorbidity burden (per unit: 1.11, 1.02-1.20), and reduced Karnofsky performance status (KPS, per 10 units: 0.62, 0.58-0.67). For low VAS score, additional determinants were transfusion dependence (1.53, 1.03-2.29), low hemoglobin <10 g/dL (1.34, 1.12-1.61), and high body mass index (≥30 vs 23-29.9 kg/m2: 1.26, 1.02-1.57). Sex, KPS, comorbidity burden, hemoglobin count, and transfusion burden were determinants for all EQ-5D dimensions. Low HRQoL is determined by multiple factors, which should be considered in the management and shared decision making of patients with MDS. This trial was registered at www.clinicaltrials.gov as #NCT00600860.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Blood advances - 7(2023), 12 vom: 27. Juni, Seite 2772-2783 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Stojkov, Igor [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical Trial |
|---|
| Anmerkungen: |
Date Completed 27.06.2023 Date Revised 10.01.2024 published: Print ClinicalTrials.gov: NCT00600860 Citation Status MEDLINE |
|---|
| doi: |
10.1182/bloodadvances.2022008360 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351189432 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351189432 | ||
| 003 | DE-627 | ||
| 005 | 20240114233319.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/bloodadvances.2022008360 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1255.xml |
| 035 | |a (DE-627)NLM351189432 | ||
| 035 | |a (NLM)36607832 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Stojkov, Igor |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Determinants of low health-related quality of life in patients with myelodysplastic syndromes |b EUMDS Registry study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.06.2023 | ||
| 500 | |a Date Revised 10.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT00600860 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. | ||
| 520 | |a Patients with myelodysplastic syndromes (MDS) frequently experience a significant symptom burden, which reduces health-related quality of life (HRQoL). We aimed to identify determinants of low HRQoL in patients recently diagnosed with MDS, for guiding early intervention strategies. We evaluated longitudinal data in 2205 patients with MDS during their first year after diagnosis. Median values of EQ-5D 3-level (EQ-5D-3L) index (0.78) and visual analog scale (VAS) score (0.70) were used as thresholds for low HRQoL. In addition, the 5 dimensions of EQ-5D-3L were analyzed for impairments (any level vs "no problem" category). After multiple imputation of missing values, we used generalized estimating equations (GEE) to estimate odds ratios (OR) for univariable determinant screening (P < .15), and to subsequently derive multivariable models for low HRQoL with 95% confidence intervals (CI). Multivariable GEE analysis showed the following independent determinants (OR, 95% CI) for low EQ-5D index: increased age (60-75 years: 1.33, 1.01-1.75; >75: 1.84, 1.39-2.45), female sex (1.70, 1.43-2.03), high serum ferritin level (≥1000 vs ≤300 μg/L: 1.41, 1.06-1.87), comorbidity burden (per unit: 1.11, 1.02-1.20), and reduced Karnofsky performance status (KPS, per 10 units: 0.62, 0.58-0.67). For low VAS score, additional determinants were transfusion dependence (1.53, 1.03-2.29), low hemoglobin <10 g/dL (1.34, 1.12-1.61), and high body mass index (≥30 vs 23-29.9 kg/m2: 1.26, 1.02-1.57). Sex, KPS, comorbidity burden, hemoglobin count, and transfusion burden were determinants for all EQ-5D dimensions. Low HRQoL is determined by multiple factors, which should be considered in the management and shared decision making of patients with MDS. This trial was registered at www.clinicaltrials.gov as #NCT00600860 | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 700 | 1 | |a Conrads-Frank, Annette |e verfasserin |4 aut | |
| 700 | 1 | |a Rochau, Ursula |e verfasserin |4 aut | |
| 700 | 1 | |a Arvandi, Marjan |e verfasserin |4 aut | |
| 700 | 1 | |a Koinig, Karin A |e verfasserin |4 aut | |
| 700 | 1 | |a Schomaker, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Mittelman, Moshe |e verfasserin |4 aut | |
| 700 | 1 | |a Fenaux, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Bowen, David |e verfasserin |4 aut | |
| 700 | 1 | |a Sanz, Guillermo F |e verfasserin |4 aut | |
| 700 | 1 | |a Malcovati, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Langemeijer, Saskia |e verfasserin |4 aut | |
| 700 | 1 | |a Germing, Ulrich |e verfasserin |4 aut | |
| 700 | 1 | |a Madry, Krzysztof |e verfasserin |4 aut | |
| 700 | 1 | |a Guerci-Bresler, Agnès |e verfasserin |4 aut | |
| 700 | 1 | |a Culligan, Dominic J |e verfasserin |4 aut | |
| 700 | 1 | |a Kotsianidis, Ioannis |e verfasserin |4 aut | |
| 700 | 1 | |a Sanhes, Laurence |e verfasserin |4 aut | |
| 700 | 1 | |a Mills, Juliet |e verfasserin |4 aut | |
| 700 | 1 | |a Puntscher, Sibylle |e verfasserin |4 aut | |
| 700 | 1 | |a Schmid, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a van Marrewijk, Corine |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Alexandra |e verfasserin |4 aut | |
| 700 | 1 | |a Efficace, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a de Witte, Theo |e verfasserin |4 aut | |
| 700 | 1 | |a Stauder, Reinhard |e verfasserin |4 aut | |
| 700 | 1 | |a Siebert, Uwe |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood advances |d 2016 |g 7(2023), 12 vom: 27. Juni, Seite 2772-2783 |w (DE-627)NLM268683263 |x 2473-9537 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2023 |g number:12 |g day:27 |g month:06 |g pages:2772-2783 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1182/bloodadvances.2022008360 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2023 |e 12 |b 27 |c 06 |h 2772-2783 | ||